Evidence map›Paper›PMID 25517314›Full record

ArticlemAbs2014

Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.

Thilipan Thaventhiran, Naif Alhumeed, Han X A Yeang, Swaminathan Sethu, Jocelyn S Downey, Ahmad F Alghanem, Adedamola Olayanju, Emma L Smith, Michael J Cross, Steven D Webb and 5 more

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2019
    Article
  3. Review
  4. Disequilibrium in the CD8Digestive diseases and sciences · 2017
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Thilipan Thaventhirana Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology ; University of Liverpool ; Liverpool , UK.
Naif Alhumeed
Han X A Yeang
Swaminathan Sethu
Jocelyn S Downey
Ahmad F Alghanem
Adedamola Olayanju
Emma L Smith
Michael J Cross
Steven D Webb
Dominic P Williams
Adrian Bristow
Christina Ball
Richard Stebbings
Jean G Sathish
Medical Research Council · GBUniversity of Liverpool · GBNational Institute for Biological Standards and Control · GBPotters Bar Community Hospital · GBWest Suffolk College · GB

Funding

Medical Research Council G0700654Medical Research Council G1000397-2/1Medical Research Council MR/L006758/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/C011205/1
6 · The paper itself

Abstract

The CD28 superagonist (CD28SA) TGN1412 was administered to humans as an agent that can selectively activate and expand regulatory T cells but resulted in uncontrolled T cell activation accompanied by cytokine storm. The molecular mechanisms that underlie this uncontrolled T cell activation are unclear. Physiological activation of T cells leads to upregulation of not only activation molecules but also inhibitory receptors such as PD-1. We hypothesized that the uncontrolled activation of CD28SA-stimulated T cells is due to both the enhanced expression of activation molecules and the lack of or reduced inhibitory signals. In this study, we show that anti-CD3 antibody-stimulated human T cells undergo time-limited controlled DNA synthesis, proliferation and interleukin-2 secretion, accompanied by PD-1 expression. In contrast, CD28SA-activated T cells demonstrate uncontrolled activation parameters including enhanced expression of LFA-1 and CCR5 but fail to express PD-1 on the cell surface. We demonstrate the functional relevance of the lack of PD-1 mediated regulatory mechanism in CD28SA-stimulated T cells. Our findings provide a molecular explanation for the dysregulated activation of CD28SA-stimulated T cells and also highlight the potential for the use of differential expression of PD-1 as a biomarker of safety for T cell immunostimulatory biologics.

Indexed as

Antibodies, Monoclonal, HumanizedBlotting, WesternCD28 AntigensCD4-Positive T-LymphocytesCell AdhesionCell MovementCell ProliferationCells, CulturedEndothelial CellsFlow CytometryHumansImmunologic MemoryLymphocyte Function-Associated Antigen-1Membrane ProteinsMicroscopy, FluorescenceProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedCCR5 protein, humanCD28 AntigensLymphocyte Function-Associated Antigen-1Membrane ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CCR5TGN-1412APC, antigen presenting cellCCR5, C-C chemokine receptor type 5CD28SA, CD28 superagonistCD28 superagonistCK2, casein kinase 2CTLA-4, cytotoxic T-Lymphocyte Antigen 4IFNγ, interferon gammaIL-2, interleukin 2immunostimulatory biologicsLAG-3, Lymphocyte-activation gene 3LFA-1, lymphocyte function-associated antigen 1MFI, mean fluorescence intensityPBMC, peripheral blood mononuclear cellsPD-1PD-1, programmed cell death protein 1PD-L1, programmed cell death-ligand 1PTEN, phosphatase and tensin homologS-phase, synthesis phaseT cellsTCR, T cell receptorTEMs, effector memory T cellsTGN1412TIM-3, T cell immunoglobulin mucin 3

Identifiers

PMID25517314
PMCPMC4622985
OpenAlexW2060061090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.